View Menu
Nightlife
A randomised control trial to assess the effectiveness and cost-effectiveness of thrice-weekly, in centre nocturnal dialysis.
Key aim:
People who choose to do more dialysis may feel better and live longer for other, completely unrelated reasons. The only way to know for sure is to compare longer treatment times with conventional treatment schedules in a well-designed clinical trial.
Read moreBioimpedance spectroscopy to maintain renal output: The BISTRO trial
The purpose of the trial is to test whether taking regular measurements with a bioimpedance device, which gives information about body composition, improves outcomes for people who have recently started haemodialysis treatment for their kidney failure.
One of the main functions of dialysis is to control the amount of fluid in the body; too much or too little fluid can lead to harm. Bioimpedance (BI) is a simple, bedside measurement giving information about body composition, in particular how much excess fluid is present. Clinicians can use this to guide how much fluid should be removed by dialysis in conjunction with the normal clinical assessment of the amount of fluid in the body, but it is not known if this results in better decisions and outcomes for patients.
Read moreAnticoagulation Decisions in Advanced CKD
Facilitating active participation in anticoagulant decisions in advanced kidney disease.
Key Aims:
To co-produce materials to support shared-decision making for anticoagulant use in CKD to be used by clinicians and patients.
People with CKD have higher risks of bleeding episodes than those with standard kidney function. There is a delicate balance between bleeding risk and thrombosis prevention, making anticoagulant treatment decisions challenging. Collaboration and shared decision making should be encouraged as part of patient treatment however, evidence regarding anticoagulation therapy in CKD is limited.
Read morePatient and Care-partners Needs
- Annually 500,000 acute kidney events are associated with 25% mortality and £1Bn hospital care spend
- Kidney care was the worst impacted clinical area during the pandemic and kidney patients faced the highest death rates, with hospitals rapidly exhausting supplies of life-saving treatment consumables
- Whilst 10% of UK adults live with kidney disease, 50% of these remain under-recognised, with low income, disability, minority groups and those of working age disproportionately affected by faster progression to dialysis, and limited access to transplantation, highlighting stark inequalities in healthcare access and outcomes
Our Vision
- Create a connected ecosystem focused on Renal Healthech to bring personalised care closer to home, reduce distress and burden of care pathways, and close care gaps affecting underserved communities
- Shift to home-based care enabling better access, outcomes, and care experience
- Contribute to High Impact objectives set out by NHSE which are at the heart of the D4D core vision of empowerment, dignity, independence and equity, addressing unmet needs from stakeholders’ perspectives
Our Approach
Our work is focused on 3 specific domains:
- Creating personalised treatments and their uptake in home environments across the kidney care pathway
- Improve dignity, independence and lowering distress with technology-based solutions
- Address inequality in health access and outcomes to prevent, diagnose and treat kidney disease
- We will focus on these areas by effectively validating new innovations, devices and solutions, working with innovators, post-device/solution creation and providing an open platform renal network to support translation of ideas to a successful end point
